Global Renal Biomarker Market Expected to Reach US$ 1,770.3 Million by 2026 - FMI
Renal Biomarker Market: Rising Prevalence of Renal Diseases Fuelling Demand for Renal Biomarkers: Global Industry Analysis and Opportunity Assessment, 2016-2026
Valley Cottage, NY, December 7, 2017 (Newswire.com) - Renal biomarkers help analyze or recognize if the patient is in danger of developing kidney infections, by measuring their urine or blood levels. They are usually discharged with intense or chronic kidney injuries that are portrayed by the gradual or rapid loss of kidney operation coming about into serious clinical ramifications. There is a looming requirement for particular and sensitive biomarkers which can distinguish kidney infections at a very primitive stage. The early distinguishing helps to make opportune preventive steps, prior to the harm winds up noticeably irreversible.
The worldwide market for renal biomarker is estimated to record a 7.0% CAGR over the projection period of 2016–2026 and is expected to account for a market value of about US$ 1,770.3 Million by 2026 end.
Get Sample of this Research Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1731
Outline by biomarker type
The overall market is segmented as
• Up-Regulated Proteins
o Interleukin 18
o Kidney injury molecule 1
o Neutrophil gelatinase-associated lipocalin
• Functional Biomarker
o Urine Albumin
o Serum Cystatin C
o Serum Creatinine
The functional biomarker accounted for 52.3% of market value share by 2016 end and is anticipated to remain dominant during the projection period. The up-regulated protein accounted for around 33.8% of market share in valuation terms by 2016 end and is expected to gain more.
Outline by diagnostic technique
The worldwide market is categorized into
• Liquid Chromatography-Mass Spectrometry
• Chemiluminescent Enzyme Immunoassay
• Colorimetric Assay
• Particle-Enhanced Turbidimetric Immunoassay
• Enzyme-Linked Immunosorbent Assay
The enzyme-linked immunosorbent assay category is likely to record an 8.1% CAGR during 2016-2026. The particle-enhanced turbidimetric immunoassay category is considered as the second largest category in value term and gained a value share of 21.0% of the overall market by 2016 end.
Outline by end user
The overall market is categorized as
• Research Centres
• Outpatient Clinics
• Diagnostic Labs
The diagnostic lab's category accounted for 34.2% of market share of the worldwide market renal biomarker in terms of revenue through 2016 and is likely to record high growth over the assessment period. The outpatient clinic's category is considered to exhibit a 7.2% CAGR throughout the calculated period.
Outline by region
The overall market is studied across the seven key regions, namely
• Latin America
• Eastern Europe
• North America
• Western Europe
• Asia Pacific Excluding Japan (APEJ)
• Middle East & Africa (MEA)
North America regional market accounted for approximately 32.2% of the revenue share of the worldwide market through 2016, followed by Western Europe. The region was projected to gain market share of 21.1% through 2016 end.
Key Market Players
The major players operating in the worldwide market for renal biomarker include
· Thermo Fisher Scientific Inc.
· Beckman Coulter Inc. (Danaher Corporation)
· BIOPORTO A/S
· Abbott Laboratories
· Randox Laboratories Ltd.
· Astute Medical Inc.
Get Full Report on Renal Biomarker Market: https://www.futuremarketinsights.com/checkout/1731
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
T (UK): +44(0)20-7692-8790
Source: Future Market Insights